Effects of l -Arginine on Fibroblast Growth Factor 2–Induced Angiogenesis in a Model of Endothelial Dysfunction
| Autor: | Tamer Malik, Cesario Bianchi, Pierre Voisine, Tanveer A. Khan, Yasunari Nakai, Jun Feng, Audrey Rosinberg, Frank W. Sellke, Marc Ruel, Jian Li, Shu-Hua Xu |
|---|---|
| Rok vydání: | 2005 |
| Předmět: |
medicine.medical_specialty
Nitric Oxide Synthase Type III Endothelium Swine Angiogenesis Nitric Oxide Synthase Type II Coronary Artery Disease Arginine Nitric Oxide Nitric oxide Coronary artery disease chemistry.chemical_compound Coronary Circulation Physiology (medical) Internal medicine medicine Animals Receptor Fibroblast Growth Factor Type 1 Endothelial dysfunction Drug Implants Membrane Glycoproteins biology business.industry Microcirculation Drug Synergism medicine.disease Nitric oxide synthase Arterioles Endocrinology medicine.anatomical_structure chemistry Models Animal biology.protein Diet Atherogenic Swine Miniature Angiogenesis Inducing Agents Fibroblast Growth Factor 2 Proteoglycans Syndecan-4 Endothelium Vascular Cardiology and Cardiovascular Medicine business Perfusion Artery |
| Zdroj: | Circulation. 112 |
| ISSN: | 1524-4539 0009-7322 |
| DOI: | 10.1161/circulationaha.104.526350 |
| Popis: | Background— Nitric oxide availability, which is decreased in advanced coronary artery disease associated with endothelial dysfunction, is an important mediator of fibroblast growth factor-2 (FGF-2)–induced angiogenesis. This could explain the disappointing results of FGF-2 therapy in clinical trials despite promising preclinical studies. We examined the influence of l -arginine supplementation to FGF-2 therapy on myocardial microvascular reactivity and perfusion in a porcine model of endothelial dysfunction. Methods and Results— Eighteen pigs were fed either a normal (NORM, n=6) or high cholesterol diet, with (HICHOL-ARG, n=6) or without (HICHOL, n=6) l -arginine. All pigs underwent ameroid placement on the circumflex artery and 3 weeks later received surgical FGF-2 treatment. Four weeks after treatment, endothelial-dependent coronary microvascular responses and lateral myocardial perfusion were assessed. Endothelial cell density was determined by immunohistochemistry. FGF-2, fibroblast growth receptor-1, endothelial-derived nitric oxide synthase (eNOS), inducible nitric oxide synthase (iNOS), and syndecan-4 levels were determined by immunoblotting. Pigs from the HICHOL group showed endothelial dysfunction in the circumflex territory, which was normalized by l -arginine supplementation. FGF-2 treatment was ineffective in the HICHOL group (circumflex/left anterior descending blood flow ratios: 1.01 (rest) and 1.01 (pace), after and before treatment). Addition of l -arginine improved myocardial perfusion in response to FGF-2 at rest (ratio 1.13, P =0.02 versus HICHOL) but not during pacing (ratio 0.94, P =NS), and was associated with increased protein levels of iNOS and eNOS. Conclusion— l -arginine supplementation can partially restore the normal response to endothelium-dependent vasorelaxants and myocardial perfusion in response to FGF-2 treatment in a swine model of hypercholesterolemia-induced endothelial dysfunction. These findings suggest a role for l -arginine in combination with FGF-2 therapy for end-stage coronary artery disease. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|